What is the recommended dose of Valtrex (valacyclovir) for treating herpes simplex virus infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Valacyclovir (Valtrex) Dosing for Herpes Simplex Virus Infections

For genital herpes, use valacyclovir 1 gram twice daily for 7-10 days for initial episodes, 500 mg twice daily for 3-5 days for recurrent episodes, and 500-1000 mg once daily for suppressive therapy depending on recurrence frequency. 1

Initial Episode of Genital Herpes

The FDA-approved dose is 1 gram twice daily for 10 days, with treatment most effective when started within 48 hours of symptom onset. 1

  • Therapy may be extended beyond 10 days if healing is incomplete 2
  • This regimen has been shown equivalent in efficacy to acyclovir 200 mg five times daily 3, 4

Recurrent Episodes

For episodic treatment of recurrences, use 500 mg twice daily for 3 days, initiated at the first sign or symptom of an episode. 1

  • Alternative regimens include 500 mg twice daily for 5 days, which is equally effective 5, 6
  • Treatment is most beneficial when started during prodrome or within 1 day of lesion onset 5
  • A once-daily 1000 mg dose for 5 days is therapeutically equivalent to 500 mg twice daily 6

Suppressive Therapy

For chronic suppression in immunocompetent patients, use 1 gram once daily; for those with 9 or fewer recurrences per year, 500 mg once daily is an acceptable alternative. 1

  • Daily suppressive therapy reduces recurrence frequency by ≥75% in patients with frequent episodes 7
  • The 500 mg once-daily dose is less effective in patients with ≥10 episodes per year 5, 7
  • Safety and efficacy documented for up to 6 years with acyclovir and 1 year with valacyclovir 5
  • After 1 year of continuous therapy, consider discontinuation to reassess recurrence rate, as frequency often decreases over time 7

Special Populations

For HIV-infected patients with CD4+ count ≥100 cells/mm³, use 500 mg twice daily for suppressive therapy. 7, 1

  • Higher dosing is recommended for immunocompromised patients due to more severe and frequent recurrences 7
  • Avoid doses of 8 grams per day in immunocompromised patients due to risk of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. 7, 8

Cold Sores (Herpes Labialis)

For cold sores in patients ≥12 years, use 2 grams twice daily for 1 day, taken 12 hours apart. 1

  • Initiate at the earliest symptom (tingling, itching, or burning) 1

Severe Disease

For severe HSV requiring hospitalization (disseminated infection, encephalitis, pneumonitis, hepatitis), use IV acyclovir 5-10 mg/kg every 8 hours for 5-7 days instead of oral valacyclovir. 5, 2

Renal Dosing

No dose reduction is needed for creatinine clearance 30-49 mL/min, but caution and potential adjustment are required for more severe renal impairment. 7, 9

  • No laboratory monitoring is needed for patients on suppressive therapy unless substantial renal impairment exists 7

Treatment Failure and Resistance

If lesions persist after 7-10 days of appropriate valacyclovir therapy, consider HSV resistance. 7

  • All acyclovir-resistant strains are also resistant to valacyclovir 7, 2
  • For acyclovir-resistant HSV, IV foscarnet 40 mg/kg every 8 hours until clinical resolution is the treatment of choice. 7, 2

Important Clinical Considerations

  • Valacyclovir may be given without regard to meals 1
  • Suppressive therapy reduces but does not eliminate asymptomatic viral shedding 7
  • Valacyclovir provides 3-5 fold better oral bioavailability than acyclovir, allowing more convenient dosing 8, 10
  • Headache is the most commonly reported adverse effect at standard doses 8

References

Guideline

Valacyclovir Dosing for HSV-1 Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Valacyclovir. New indication: for genital herpes, simpler administration.

Canadian family physician Medecin de famille canadien, 1999

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Suppressive Therapy for Herpes Simplex Virus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Valacyclovir Dosing for Herpes Zoster Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Valaciclovir].

Annales de dermatologie et de venereologie, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.